Catheter Ablation Clinical Trial
Official title:
Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation - A Randomized Open-Label Phase III Trial
The goal of this clinical trial is to test the effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation. The main questions it aims to answer are: • If Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias [atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT)] greater than 30 seconds during one-year follow-up after catheter ablation. Participants will receive Dapagliflozin (FORXIGA) 10 milligram (mg) once a day (QD) for 3 months after catheter ablation of atrial fibrillation. Researchers will compare patients who receive usual care to see if Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias (AF/AFL/AT) during one-year follow-up after catheter ablation.
This trial is the third phase of random allocation and non-blind trial. It is divided into study group and control group. The study group is Dapagliflozin therapy, and the treatment period is three months post catheter ablation. The control group is usual care (without Dapagliflozin). The follow-up observation period will be one year after catheter ablation. This trial was performed at Kaohsiung Chang Gung Memorial Hospital and Chang Gung Memorial Hospital, Linkou, and Chiayi branches, and it is a multi-center trial. The study flow chart is as follows. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03593486 -
Low-Level EMF Stimulation for Paroxysmal Atrial Fibrillation
|
N/A | |
| Terminated |
NCT01546207 -
Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia
|
N/A | |
| Active, not recruiting |
NCT06124690 -
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
|
N/A | |
| Recruiting |
NCT05251545 -
Randomized Trial: High Power Short Duration Versus Ablation Index
|
N/A | |
| Not yet recruiting |
NCT04780438 -
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
|
Early Phase 1 | |
| Active, not recruiting |
NCT03695484 -
Registry Evaluating AF Ablation Techniques
|
||
| Recruiting |
NCT05777850 -
High-Power Short-Duration Radiofrequency Ablation in Patients With Typical Atrial Flutter
|
N/A | |
| Not yet recruiting |
NCT05565183 -
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
|
N/A | |
| Recruiting |
NCT06160076 -
Inflammatory Response Following " Pulsed Field Ablation " vs. Radiofrequency Ablation-2
|
||
| Not yet recruiting |
NCT05575544 -
Electroacupuncture Intervention in Catheter Ablation of Atrial Fibrillation
|
N/A | |
| Recruiting |
NCT04678258 -
Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation
|
N/A | |
| Active, not recruiting |
NCT01630031 -
Contact Force Sensing and Pulmonary Vein Isolation
|
N/A | |
| Completed |
NCT04896424 -
Vagal Response and Cardiac Autonomic Modulation. Insides From Cryoballoon Ablation
|
N/A | |
| Completed |
NCT04906720 -
Post-Ablation Pericarditis Reduction Study
|
Phase 2 | |
| Not yet recruiting |
NCT05273645 -
PrOgnosis Following Esophageal fisTula formaTion in Pts Undergoing cathetER Ablation for AF Study
|
||
| Completed |
NCT03140631 -
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
|
Phase 4 | |
| Active, not recruiting |
NCT03514693 -
Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation
|
N/A | |
| Recruiting |
NCT03832959 -
Esophageal Damage Protection During Pulmonary Vein Ablation. Pilot Study.
|
N/A | |
| Not yet recruiting |
NCT05716581 -
Prognostic Factors for Ablation of Atrial Fibrillation
|
||
| Recruiting |
NCT04405258 -
Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial
|
Phase 4 |